Neurocrine Biosciences (NBIX) EBITDA Margin (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported EBITDA Margin for 16 consecutive years, with 15.8% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA Margin fell 538.0% year-over-year to 15.8%; the trailing twelve-month figure through Jun 2026 stood at 23.56% (up 384.0% YoY), and the FY2025 full-year result was 21.64%, down 258.0% from the prior year.
• EBITDA Margin retreated to 15.8% in Q2 2026 per NBIX's latest filing, from 23.74% in the prior quarter.
• Across five years, EBITDA Margin topped out at 30.07% in Q3 2025 and bottomed at 27.16% in Q1 2023.
• Historically, EBITDA Margin has averaged 18.16% across 5 years, with a median of 22.63% in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin slumped 2816 bps in 2023, then soared 4643 bps in 2024.
• Over 5 years, EBITDA Margin stood at 25.1% in 2022, then increased by 16 bps to 29.17% in 2023, then dropped by 22 bps to 22.62% in 2024, then increased by 16 bps to 26.18% in 2025, then plunged by 40 bps to 15.8% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 15.8%, 23.74%, and 26.18% for Q2 2026, Q1 2026, and Q4 2025 respectively.